MISSOULA, Mont.--(BUSINESS WIRE)--EndoBiologics and PATH have formed a new research partnership to investigate novel conjugate vaccine candidates against enteric bacteria that cause dysentery and severe diarrhea. PATH will fund EndoBiologics to complete preclinical research into process development, mucosal immunization, and evaluation of novel antigens for potential protection in animal models.
